Eli Lilly outlays $1.12bn for hearing loss gene therapy partnership [Yahoo! Finance]
MeiraGTx Holdings plc - Ordinary Shares (MGTX)
Company Research
Source: Yahoo! Finance
The partnership will see the two companies develop and commercialise programmable recombinase-based treatments targeting hearing loss indications. In exchange for using Seamless' recombinase platform, Lilly will pay the biotech over $1.12bn in an upfront payment and R&D funding. The exact breakdown of milestone payments and additional royalties on any approved drugs was not disclosed. Germany-based Seamless, which launched in 2023, uses programmable recombinases to address genetic diseases. Recombinases are specialised enzymes that catalyse site-specific DNA rearrangements, including excision, insertion, and translocation. These enzymes have been used in scientific research for decades, but only now are they being harnessed for the potential of commercialised therapies. The biotech says its platform can perform large but precise DNA edits along the genome, enabling treatment across a broad range of diseases. Following the deal with Lilly, Seamless will design and programme site-s
Show less
Read more
Impact Snapshot
Event Time:
MGTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MGTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MGTX alerts
High impacting MeiraGTx Holdings plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
MGTX
News
- ZipBio and MeiraGTx Enter into Exclusive License Agreement to Advance First-in-Class AAV Gene Therapy for Geographic AtrophyPR Newswire
- MeiraGTx (NASDAQ:MGTX) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.MarketBeat
- MeiraGTx inks $18.2M share purchase deal with Perceptive Advisors [Seeking Alpha]Seeking Alpha
- MeiraGTx (NASDAQ:MGTX) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.MarketBeat
- MeiraGTx (NASDAQ:MGTX) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock.MarketBeat
MGTX
Earnings
- 11/13/25 - Miss
MGTX
Sec Filings
- 1/21/26 - Form 4
- 1/21/26 - Form 4
- 1/21/26 - Form 4
- MGTX's page on the SEC website